SCHEMBL1469033

SCHEMBL1469033

O=C(Nc1c[nH]c2ncc(F)c(F)c12)c1cccnc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 9/20 0.59
GAA P10253 1/20 0.52
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
ABCB1 P08183 1/20 0.51
PIM1 P11309 2/20 0.51
GAK O14976 1/20 0.51
STK16 O75716 1/20 0.51
AXL P30530 1/20 0.51
NEK2 P51955 1/20 0.51
STK3 Q13188 1/20 0.51
STK11 Q15831 1/20 0.51
BMP2K Q9NSY1 1/20 0.51
TNIK Q9UKE5 1/20 0.51
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
PIM3 Q86V86 1/20 0.47
PIM2 Q9P1W9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1468749 0.88 AAK1 (0.57) AAK1GAAHDAC3HDAC1HDAC2
SCHEMBL1467820 0.88 AAK1 (0.57) AAK1GAAHDAC3HDAC1HDAC2
SCHEMBL1467964 0.79 AAK1 (0.56) AAK1PIM1GAKSTK16AXL
SCHEMBL7053845 0.77 AAK1 (0.70) AAK1HDAC3HDAC1HDAC2PIM1
SCHEMBL10272146 0.77 AAK1 (0.46) AAK1GAAHDAC3HDAC1HDAC2
SCHEMBL1468665 0.76 PIM2 (0.47) AAK1HDAC1PIM1PIM3PIM2
SCHEMBL1468662 0.76 PIM2 (0.47) AAK1HDAC1PIM1PIM3PIM2
Hydrochloric Acid SCHEMBL1467780 0.76 PIM2 (0.46) AAK1HDAC1PIM1PIM3PIM2
Hydrochloric Acid SCHEMBL1467783 0.76 PIM2 (0.46) AAK1HDAC1PIM1PIM3PIM2
SCHEMBL1468035 0.76 HDAC1 (0.45) AAK1HDAC1AXLMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969727-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-05-15 US disclosed
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-12-22 US disclosed
US-9365568-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-06-14 US disclosed
EP-2990407-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-03-02 EP disclosed
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-11-12 US disclosed
CN-104926810-A Pyrrolopyridines As Kinase Inhibitors ARRAY BIOPHARMA INC 2015-09-23 CN disclosed
EP-2307409-B1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-08-12 EP disclosed
CN-102089307-B Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC 2015-07-01 CN disclosed
US-8981085-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-17 US disclosed
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-08-28 US disclosed
US-8758830-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-06-24 US disclosed
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-04-10 US disclosed
US-8545897-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-01 US disclosed
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-02-21 US disclosed
US-8178131-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-05-15 US disclosed
EP-2307409-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-04-13 EP disclosed
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-24 US disclosed
WO-2009140320-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A AAK1 438/4885GAA 2075/4885HDAC3 3148/4885
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A AAK1 438/4885GAA 2075/4885HDAC3 3148/4885
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A AAK1 438/4885GAA 2075/4885HDAC3 3148/4885
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B AAK1 453/4885GAA 1849/4885HDAC3 2749/4885
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A AAK1 438/4885GAA 2075/4885HDAC3 3148/4885
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A AAK1 438/4885GAA 2075/4885HDAC3 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.